Close

Medicines Co. (MDCO) Receives $132M HHS Grant, Enters Partnership with BARDA for Gram-Negative Infections Antibiotics

Go back to Medicines Co. (MDCO) Receives $132M HHS Grant, Enters Partnership with BARDA for Gram-Negative Infections Antibiotics

The Medicines Company Awarded up to $132 Million to Develop Portfolio of New Antibiotics Targeting Drug-Resistant Infections under Strategic Partnership with BARDA

September 21, 2016 7:30 AM EDT

Provides up to $132 million to support development of the Companys leading pipeline of antibiotics targeting drug-resistant bacteria, including the ongoing development of CARBAVANCE® (meropenem-vaborbactam)

First portfolio-based strategic partnership between the Biomedical Advanced Research and Development Authority (BARDA) and a U.S. headquartered company

Strategic partnership evidences the leadership position of The Medicines Companys Infectious Disease Business, its proven track record of innovative research and development and the strength of its growing commercial capabilities

Builds on the success of the Companys existing agreement with BARDA... More